- Home
- EXFY vs ORIC Comparison
EXFY vs ORIC Comparison
Compare EXFY & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- ORIC
- Stock Information
- Founded
- EXFY 2008
- ORIC 2014
- Country
- EXFY United States
- ORIC United States
- Employees
- EXFY N/A
- ORIC N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- ORIC Health Care
- Exchange
- EXFY Nasdaq
- ORIC Nasdaq
- Market Cap
- EXFY 309.9M
- ORIC 362.9M
- IPO Year
- EXFY 2021
- ORIC 2020
- Fundamental
- Price
- EXFY $2.78
- ORIC $4.77
- Analyst Decision
- EXFY Buy
- ORIC Strong Buy
- Analyst Count
- EXFY 4
- ORIC 9
- Target Price
- EXFY $5.00
- ORIC $18.43
- AVG Volume (30 Days)
- EXFY 338.3K
- ORIC 969.8K
- Earning Date
- EXFY 05-08-2025
- ORIC 05-05-2025
- Dividend Yield
- EXFY N/A
- ORIC N/A
- EPS Growth
- EXFY N/A
- ORIC N/A
- EPS
- EXFY N/A
- ORIC N/A
- Revenue
- EXFY $139,236,000.00
- ORIC N/A
- Revenue This Year
- EXFY $9.56
- ORIC N/A
- Revenue Next Year
- EXFY $6.86
- ORIC N/A
- P/E Ratio
- EXFY N/A
- ORIC N/A
- Revenue Growth
- EXFY N/A
- ORIC N/A
- 52 Week Low
- EXFY $1.24
- ORIC $3.90
- 52 Week High
- EXFY $4.13
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- EXFY 42.68
- ORIC 37.10
- Support Level
- EXFY $2.65
- ORIC $3.90
- Resistance Level
- EXFY $2.87
- ORIC $5.38
- Average True Range (ATR)
- EXFY 0.21
- ORIC 0.53
- MACD
- EXFY 0.01
- ORIC 0.06
- Stochastic Oscillator
- EXFY 47.62
- ORIC 41.97
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.